Lv3
266 积分 2021-10-24 加入
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer
13天前
已完结
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
21天前
已完结
RET, ROS1 and ALK fusions in lung cancer
1个月前
已完结
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study
1个月前
已完结
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features
1个月前
已完结
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
1个月前
已完结
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer
1个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
3个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
3个月前
已完结
EGFR-TKIs耐药后应对策略及标准化质量控制中国专家共识
3个月前
已完结
皖公网安备34019202002308
